

# Philip N Patsalos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8349063/philip-n-patsalos-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

4,459  
citations

28  
h-index

66  
g-index

121  
ext. papers

5,164  
ext. citations

5.5  
avg, IF

6.02  
L-index

#	Paper	IF	Citations
85	Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , <b>2008</b> , 49, 1239-76	6.4	703
84	The importance of drug interactions in epilepsy therapy. <i>Epilepsia</i> , <b>2002</b> , 43, 365-85	6.4	336
83	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , <i>The</i> , <b>2003</b> , 2, 347-56	24.1	321
82	Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. <i>Lancet Neurology</i> , <i>The</i> , <b>2003</b> , 2, 473-81	24.1	302
81	Clinical pharmacokinetics of levetiracetam. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 707-24	6.2	287
80	Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. <i>Epilepsia</i> , <b>2000</b> , 41, 1364-74	6.4	261
79	Therapeutic drug monitoring of the newer antiepileptic drugs. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 347-63	3.2	245
78	Drug interactions involving the new second- and third-generation antiepileptic drugs. <i>Expert Review of Neurotherapeutics</i> , <b>2010</b> , 10, 119-40	4.3	221
77	Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 526-548	3.2	167
76	The new generation of GABA enhancers. Potential in the treatment of epilepsy. <i>CNS Drugs</i> , <b>2001</b> , 15, 339-50	6.7	151
75	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. <i>Epilepsia</i> , <b>2015</b> , 56, 12-27	6.4	146
74	Therapeutic drug monitoring of antiepileptic drugs by use of saliva. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 4-29	3.2	126
73	Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 927-66	6.2	124
72	Investigation into the role of N-acetylaspartate in cerebral osmoregulation. <i>Journal of Neurochemistry</i> , <b>1995</b> , 65, 275-81	6	112
71	Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. <i>Epilepsia</i> , <b>2005</b> , 46 Suppl 9, 140-8	6.4	89
70	Antiepileptic drugs. A review of clinically significant drug interactions. <i>Drug Safety</i> , <b>1993</b> , 9, 156-84	5.1	80
69	Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 1045-61	6.2	77

68	Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. <i>Epilepsia</i> , <b>2017</b> , 58, 1234-1243	6.4	67
67	Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?. <i>Epilepsy and Behavior</i> , <b>2011</b> , 20, 20-3	3.2	62
66	Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. <i>Epilepsy Research</i> , <b>2002</b> , 48, 217-9	3	47
65	Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 358-64	3.2	44
64	Saliva and serum lacosamide concentrations in patients with epilepsy. <i>Epilepsia</i> , <b>2011</b> , 52, 258-63	6.4	43
63	Newer antiepileptic drugs. Towards an improved risk-benefit ratio. <i>Drug Safety</i> , <b>1994</b> , 11, 37-67	5.1	42
62	Benzodiazepine-GABAA receptors in idiopathic generalized epilepsy measured with [ <sup>11</sup> C]flumazenil and positron emission tomography. <i>Epilepsia</i> , <b>1995</b> , 36, 113-21	6.4	41
61	In situ metabolism of levetiracetam in blood of patients with epilepsy. <i>Epilepsia</i> , <b>2006</b> , 47, 1818-21	6.4	39
60	Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 699-715	4	31
59	Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. <i>Epilepsia</i> , <b>1991</b> , 32, 101-15	6.4	30
58	Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 494-8	3.2	29
57	Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 15-20	3.2	28
56	New Antiepileptic Drugs. <i>CNS Drugs</i> , <b>1994</b> , 2, 40-77	6.7	27
55	Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. <i>Epilepsia</i> , <b>2020</b> , 61, 1854-1868	6.4	26
54	Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 227-238	5.5	18
53	Methodologies used to identify and characterize interactions among antiepileptic drugs. <i>Expert Review of Clinical Pharmacology</i> , <b>2012</b> , 5, 281-92	3.8	18
52	Volumetric Absorptive Microsampling: A New Sampling Tool for Therapeutic Drug Monitoring of Antiepileptic Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 681-692	3.2	17
51	The Epilepsy Prescriber's Guide to Antiepileptic Drugs <b>2010</b> ,		16

50	Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 765-9	3.8	15
49	Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. <i>Seizure: the Journal of the British Epilepsy Association</i> , <b>2017</b> , 48, 1-6	3.2	14
48	New developments in the treatment of partial-onset epilepsy. <i>Neuropsychiatric Disease and Treatment</i> , <b>2012</b> , 8, 455-64	3.1	11
47	Perampanel: What is its Place in the Management of Partial Onset Epilepsy?. <i>Neurology and Therapy</i> , <b>2013</b> , 2, 13-24	4.6	9
46	Predictability of metabolic antiepileptic drug interactions <b>2005</b> , 57-92		5
45	Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. <i>Neuropsychiatric Disease and Treatment</i> , <b>2016</b> , 12, 1215-20	3.1	5
44	Antiepileptic drug interactions in patients requiring psychiatric drug treatment <b>2005</b> , 350-368		4
43	The new generation of anti-epileptic drugs. <i>Expert Opinion on Emerging Drugs</i> , <b>1999</b> , 4, 87-106		3
42	Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study. <i>BMC Neurology</i> , <b>2020</b> , 20, 7	3.1	3
41	The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy. <i>Epilepsy Research</i> , <b>2018</b> , 148, 17-22	3	2
40	Interactions between antiepileptic drugs <b>2005</b> , 111-138		1
39	Antiepileptic drug interactions in the elderly <b>2005</b> , 273-293		1
38	Antiepileptic drugs in non-epileptic health conditions: possible interactions <b>2005</b> , 369-391		1
37	Interactions between antiepileptic and non-antiepileptic drugs <b>2005</b> , 139-178		1
36	Combination therapy of diseases: general concepts <b>2005</b> , 3-15		1
35	Influence of food and drugs on the bioavailability of antiepileptic drugs <b>2005</b> , 93-110		1
34	Pharmacodynamic principles and mechanisms of drug interactions <b>2005</b> , 181-192		1
33	Methods for assessing pharmacodynamic interactions <b>2005</b> , 193-207		1

32	Experimental studies of pharmacodynamic interactions <b>2005</b> , 208-227	1
31	Clinical studies of pharmacodynamic interactions between antiepileptic drugs and other drugs <b>2005</b> , 241-254	1
30	Combination therapy with antiepileptic drugs: potential advantages and problems <b>2005</b> , 16-25	1
29	Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy <b>2019</b> , 50,	1
28	Clinically Important Antiepileptic Drug Interactions and their Influence on Adverse effects in Epilepsy <b>2015</b> , 110-119	
27	Eslicarbazepine acetate57-65	
26	Perampanel180-187	
25	Retigabine / ezogabine237-245	
24	Antiepileptic Drug Interactions <b>2014</b> , 91-101	
23	Metabolism-Based Consequences of Polytherapy with Antiepileptic Drugs <b>2012</b> , 1	
22	Antiepileptic drug interactions in children <b>2005</b> , 257-272	
21	Cognitive side-effects due to antiepileptic drug combinations and interactions <b>2005</b> , 403-418	
20	Pharmacogenetic aspects <b>2005</b> , 26-44	
19	Pharmacokinetic principles and mechanisms of drug interactions <b>2005</b> , 47-56	
18	Clinical studies of pharmacodynamic interactions <b>2005</b> , 228-240	
17	Antiepileptic drug interactions in pregnancy <b>2005</b> , 294-324	
16	Antiepileptic drug interactions in handicapped and mentally retarded patients <b>2005</b> , 325-340	
15	Antiepileptic drugs and sex steroids <b>2005</b> , 341-349	

14 Drug monitoring in combination therapy **2005**, 392-402

13 Selection of drug combinations in clinical practice: current and future perspectives **2005**, 421-440

12 Future research: an experimental perspective **2005**, 441-457

11 Future research: a clinical prospective **2005**, 458-474

10 Stiripentol **2022**, 147-150

9 Clobazam **2022**, 55-59

8 Psychotropic Drugs **2022**, 319-335

7 Cannabidiol **2022**, 39-42

6 Perampanel **2022**, 113-116

5 Perampanel **2022**, 227-227

4 Perampanel **2016**, 77-80

3 Psychotropic Drugs **2016**, 285-301

2 Clobazam **2016**, 23-27

1 Perampanel **2016**, 191-191